2
|
Kim GB, Pacheco DRF, Saxon D, Yang A, Sabat S, Dutra-Clarke M, Levy R, Watkins A, Park H, Akhtar AA, Linesch PW, Kobritz N, Shandra SS, Grausam K, Ayala-Sarmiento A, Molina J, Sedivakova K, Gareau DS, Filbin MG, Bannykh S, Tang J, Suva ML, Chen B, Danielpour M, Breunig JJ. Abstract NG01: MADR: Rapid generation of somatic mosaics to model cancer in mice and human organoids. Cancer Res 2020. [DOI: 10.1158/1538-7445.am2020-ng01] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
In situ transgenesis methods such as virus and electroporation can create somatic transgenic mice quickly, but they lack the exquisite control over copy number, zygosity, and locus specificity. We have recently established mosaic analysis by dual recombinase-mediated cassette exchange (MADR), which permits stable labeling of mutant cells expressing transgenic elements from precisely-defined chromosomal loci. MADR provides a toolkit of elements for combinatorial labeling, inducible/reversible transgene manipulation, VCre recombinase expression, and genetic manipulation of human cells. Further, we have demonstrated the versatility of MADR by creating glioma models with mixed, reporter-identified zygosity or with “personalized” driver mutations from pediatric glioma. For example, introducing H3f3a mutation variants with MADR regulates the spatiotemporal profile of glioma, and single-cell RNA and ATAC sequencing analysis demonstrates a recapitulation of developmental hierarchy seen in K27M-mutant human glioma. Moreover, we have generated novel models of supratentorial ependymoma using patient-derived oncofusion transgenes. These models display a high degree of fidelity and we now compare these models on a single-cell level with our previous models and human tumor cell transcriptomes. In addition, we now demonstrate the ability to generalize the MADR technology to other non-CNS tissues using local plasmid delivery. Finally, we have engineered human cells to allow for MADR transgenesis and somatic transgenic organoids. These combined approaches will enable researchers to discovery disease mechanisms and test therapeutics in more physiologically relevant cancer models.MADR is extensible to thousands of existing mouse lines and can be adapted to human cells, providing a flexible platform to democratize the generation of somatic transgenic disease models.
Citation Format: Gi Bum Kim, David Rincon Fernandez Pacheco, David Saxon, Amy Yang, Sara Sabat, Marina Dutra-Clarke, Rachelle Levy, Ashley Watkins, Hannah Park, Aslam Abbasi Akhtar, Paul W. Linesch, Naomi Kobritz, Swasty S. Shandra, Katie Grausam, Alberto Ayala-Sarmiento, Jessica Molina, Kristyna Sedivakova, Daniel S. Gareau, Mariella G. Filbin, Serguei Bannykh, Jie Tang, Mario L. Suva, Bin Chen, Moise Danielpour, Joshua J. Breunig. MADR: Rapid generation of somatic mosaics to model cancer in mice and human organoids [abstract]. In: Proceedings of the Annual Meeting of the American Association for Cancer Research 2020; 2020 Apr 27-28 and Jun 22-24. Philadelphia (PA): AACR; Cancer Res 2020;80(16 Suppl):Abstract nr NG01.
Collapse
Affiliation(s)
- Gi Bum Kim
- Cedars-Sinai Medical Center, Los Angeles, CA, Rockefeller University, New York, NY, Dana Farber Boston Children's Cancer and Blood Disorder Center, Boston, MA, Broad Institute of MIT and Harvard, Cambridge, MA, University of California Santa Cruz, Santa Cruz, CA
| | - David Rincon Fernandez Pacheco
- Cedars-Sinai Medical Center, Los Angeles, CA, Rockefeller University, New York, NY, Dana Farber Boston Children's Cancer and Blood Disorder Center, Boston, MA, Broad Institute of MIT and Harvard, Cambridge, MA, University of California Santa Cruz, Santa Cruz, CA
| | - David Saxon
- Cedars-Sinai Medical Center, Los Angeles, CA, Rockefeller University, New York, NY, Dana Farber Boston Children's Cancer and Blood Disorder Center, Boston, MA, Broad Institute of MIT and Harvard, Cambridge, MA, University of California Santa Cruz, Santa Cruz, CA
| | - Amy Yang
- Cedars-Sinai Medical Center, Los Angeles, CA, Rockefeller University, New York, NY, Dana Farber Boston Children's Cancer and Blood Disorder Center, Boston, MA, Broad Institute of MIT and Harvard, Cambridge, MA, University of California Santa Cruz, Santa Cruz, CA
| | - Sara Sabat
- Cedars-Sinai Medical Center, Los Angeles, CA, Rockefeller University, New York, NY, Dana Farber Boston Children's Cancer and Blood Disorder Center, Boston, MA, Broad Institute of MIT and Harvard, Cambridge, MA, University of California Santa Cruz, Santa Cruz, CA
| | - Marina Dutra-Clarke
- Cedars-Sinai Medical Center, Los Angeles, CA, Rockefeller University, New York, NY, Dana Farber Boston Children's Cancer and Blood Disorder Center, Boston, MA, Broad Institute of MIT and Harvard, Cambridge, MA, University of California Santa Cruz, Santa Cruz, CA
| | - Rachelle Levy
- Cedars-Sinai Medical Center, Los Angeles, CA, Rockefeller University, New York, NY, Dana Farber Boston Children's Cancer and Blood Disorder Center, Boston, MA, Broad Institute of MIT and Harvard, Cambridge, MA, University of California Santa Cruz, Santa Cruz, CA
| | - Ashley Watkins
- Cedars-Sinai Medical Center, Los Angeles, CA, Rockefeller University, New York, NY, Dana Farber Boston Children's Cancer and Blood Disorder Center, Boston, MA, Broad Institute of MIT and Harvard, Cambridge, MA, University of California Santa Cruz, Santa Cruz, CA
| | - Hannah Park
- Cedars-Sinai Medical Center, Los Angeles, CA, Rockefeller University, New York, NY, Dana Farber Boston Children's Cancer and Blood Disorder Center, Boston, MA, Broad Institute of MIT and Harvard, Cambridge, MA, University of California Santa Cruz, Santa Cruz, CA
| | - Aslam Abbasi Akhtar
- Cedars-Sinai Medical Center, Los Angeles, CA, Rockefeller University, New York, NY, Dana Farber Boston Children's Cancer and Blood Disorder Center, Boston, MA, Broad Institute of MIT and Harvard, Cambridge, MA, University of California Santa Cruz, Santa Cruz, CA
| | - Paul W. Linesch
- Cedars-Sinai Medical Center, Los Angeles, CA, Rockefeller University, New York, NY, Dana Farber Boston Children's Cancer and Blood Disorder Center, Boston, MA, Broad Institute of MIT and Harvard, Cambridge, MA, University of California Santa Cruz, Santa Cruz, CA
| | - Naomi Kobritz
- Cedars-Sinai Medical Center, Los Angeles, CA, Rockefeller University, New York, NY, Dana Farber Boston Children's Cancer and Blood Disorder Center, Boston, MA, Broad Institute of MIT and Harvard, Cambridge, MA, University of California Santa Cruz, Santa Cruz, CA
| | - Swasty S. Shandra
- Cedars-Sinai Medical Center, Los Angeles, CA, Rockefeller University, New York, NY, Dana Farber Boston Children's Cancer and Blood Disorder Center, Boston, MA, Broad Institute of MIT and Harvard, Cambridge, MA, University of California Santa Cruz, Santa Cruz, CA
| | - Katie Grausam
- Cedars-Sinai Medical Center, Los Angeles, CA, Rockefeller University, New York, NY, Dana Farber Boston Children's Cancer and Blood Disorder Center, Boston, MA, Broad Institute of MIT and Harvard, Cambridge, MA, University of California Santa Cruz, Santa Cruz, CA
| | - Alberto Ayala-Sarmiento
- Cedars-Sinai Medical Center, Los Angeles, CA, Rockefeller University, New York, NY, Dana Farber Boston Children's Cancer and Blood Disorder Center, Boston, MA, Broad Institute of MIT and Harvard, Cambridge, MA, University of California Santa Cruz, Santa Cruz, CA
| | - Jessica Molina
- Cedars-Sinai Medical Center, Los Angeles, CA, Rockefeller University, New York, NY, Dana Farber Boston Children's Cancer and Blood Disorder Center, Boston, MA, Broad Institute of MIT and Harvard, Cambridge, MA, University of California Santa Cruz, Santa Cruz, CA
| | - Kristyna Sedivakova
- Cedars-Sinai Medical Center, Los Angeles, CA, Rockefeller University, New York, NY, Dana Farber Boston Children's Cancer and Blood Disorder Center, Boston, MA, Broad Institute of MIT and Harvard, Cambridge, MA, University of California Santa Cruz, Santa Cruz, CA
| | - Daniel S. Gareau
- Cedars-Sinai Medical Center, Los Angeles, CA, Rockefeller University, New York, NY, Dana Farber Boston Children's Cancer and Blood Disorder Center, Boston, MA, Broad Institute of MIT and Harvard, Cambridge, MA, University of California Santa Cruz, Santa Cruz, CA
| | - Mariella G. Filbin
- Cedars-Sinai Medical Center, Los Angeles, CA, Rockefeller University, New York, NY, Dana Farber Boston Children's Cancer and Blood Disorder Center, Boston, MA, Broad Institute of MIT and Harvard, Cambridge, MA, University of California Santa Cruz, Santa Cruz, CA
| | - Serguei Bannykh
- Cedars-Sinai Medical Center, Los Angeles, CA, Rockefeller University, New York, NY, Dana Farber Boston Children's Cancer and Blood Disorder Center, Boston, MA, Broad Institute of MIT and Harvard, Cambridge, MA, University of California Santa Cruz, Santa Cruz, CA
| | - Jie Tang
- Cedars-Sinai Medical Center, Los Angeles, CA, Rockefeller University, New York, NY, Dana Farber Boston Children's Cancer and Blood Disorder Center, Boston, MA, Broad Institute of MIT and Harvard, Cambridge, MA, University of California Santa Cruz, Santa Cruz, CA
| | - Mario L. Suva
- Cedars-Sinai Medical Center, Los Angeles, CA, Rockefeller University, New York, NY, Dana Farber Boston Children's Cancer and Blood Disorder Center, Boston, MA, Broad Institute of MIT and Harvard, Cambridge, MA, University of California Santa Cruz, Santa Cruz, CA
| | - Bin Chen
- Cedars-Sinai Medical Center, Los Angeles, CA, Rockefeller University, New York, NY, Dana Farber Boston Children's Cancer and Blood Disorder Center, Boston, MA, Broad Institute of MIT and Harvard, Cambridge, MA, University of California Santa Cruz, Santa Cruz, CA
| | - Moise Danielpour
- Cedars-Sinai Medical Center, Los Angeles, CA, Rockefeller University, New York, NY, Dana Farber Boston Children's Cancer and Blood Disorder Center, Boston, MA, Broad Institute of MIT and Harvard, Cambridge, MA, University of California Santa Cruz, Santa Cruz, CA
| | - Joshua J. Breunig
- Cedars-Sinai Medical Center, Los Angeles, CA, Rockefeller University, New York, NY, Dana Farber Boston Children's Cancer and Blood Disorder Center, Boston, MA, Broad Institute of MIT and Harvard, Cambridge, MA, University of California Santa Cruz, Santa Cruz, CA
| |
Collapse
|
3
|
Kim GB, Rincon Fernandez Pacheco D, Saxon D, Yang A, Sabet S, Dutra-Clarke M, Levy R, Watkins A, Park H, Abbasi Akhtar A, Linesch PW, Kobritz N, Chandra SS, Grausam K, Ayala-Sarmiento A, Molina J, Sedivakova K, Hoang K, Tsyporin J, Gareau DS, Filbin MG, Bannykh S, Santiskulvong C, Wang Y, Tang J, Suva ML, Chen B, Danielpour M, Breunig JJ. Rapid Generation of Somatic Mouse Mosaics with Locus-Specific, Stably Integrated Transgenic Elements. Cell 2020; 179:251-267.e24. [PMID: 31539496 DOI: 10.1016/j.cell.2019.08.013] [Citation(s) in RCA: 32] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/27/2018] [Revised: 05/24/2019] [Accepted: 08/06/2019] [Indexed: 12/11/2022]
Abstract
In situ transgenesis methods such as viruses and electroporation can rapidly create somatic transgenic mice but lack control over copy number, zygosity, and locus specificity. Here we establish mosaic analysis by dual recombinase-mediated cassette exchange (MADR), which permits stable labeling of mutant cells expressing transgenic elements from precisely defined chromosomal loci. We provide a toolkit of MADR elements for combination labeling, inducible and reversible transgene manipulation, VCre recombinase expression, and transgenesis of human cells. Further, we demonstrate the versatility of MADR by creating glioma models with mixed reporter-identified zygosity or with "personalized" driver mutations from pediatric glioma. MADR is extensible to thousands of existing mouse lines, providing a flexible platform to democratize the generation of somatic mosaic mice. VIDEO ABSTRACT.
Collapse
Affiliation(s)
- Gi Bum Kim
- Board of Governors Regenerative Medicine Institute, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA
| | | | - David Saxon
- Board of Governors Regenerative Medicine Institute, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA
| | - Amy Yang
- Board of Governors Regenerative Medicine Institute, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA
| | - Sara Sabet
- Board of Governors Regenerative Medicine Institute, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA; Department of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA
| | - Marina Dutra-Clarke
- Board of Governors Regenerative Medicine Institute, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA
| | - Rachelle Levy
- Board of Governors Regenerative Medicine Institute, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA
| | - Ashley Watkins
- Board of Governors Regenerative Medicine Institute, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA
| | - Hannah Park
- Board of Governors Regenerative Medicine Institute, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA; Department of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA
| | - Aslam Abbasi Akhtar
- Board of Governors Regenerative Medicine Institute, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA; Department of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA
| | - Paul W Linesch
- Board of Governors Regenerative Medicine Institute, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA; Department of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA
| | - Naomi Kobritz
- Board of Governors Regenerative Medicine Institute, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA
| | - Swasty S Chandra
- Board of Governors Regenerative Medicine Institute, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA
| | - Katie Grausam
- Board of Governors Regenerative Medicine Institute, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA
| | - Alberto Ayala-Sarmiento
- Board of Governors Regenerative Medicine Institute, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA
| | - Jessica Molina
- Board of Governors Regenerative Medicine Institute, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA
| | - Kristyna Sedivakova
- Board of Governors Regenerative Medicine Institute, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA
| | - Kendy Hoang
- Department of Molecular, Cell, and Developmental Biology, University of California, Santa Cruz, 1156 High St., Santa Cruz, CA 95064, USA
| | - Jeremiah Tsyporin
- Department of Molecular, Cell, and Developmental Biology, University of California, Santa Cruz, 1156 High St., Santa Cruz, CA 95064, USA
| | - Daniel S Gareau
- Laboratory for Investigative Dermatology, The Rockefeller University, New York, NY 10065, USA
| | - Mariella G Filbin
- Department of Pediatric Oncology, Dana-Farber Boston Children's Cancer and Blood Disorders Center, Boston, MA 02215, USA; Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA
| | - Serguei Bannykh
- Department of Pathology and Laboratory Medicine, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA
| | - Chintda Santiskulvong
- Center for Neural Sciences in Medicine, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA
| | - Yizhou Wang
- Center for Neural Sciences in Medicine, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA
| | - Jie Tang
- Center for Neural Sciences in Medicine, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA
| | - Mario L Suva
- Department of Pathology and Center for Cancer Research, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA; Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA
| | - Bin Chen
- Department of Molecular, Cell, and Developmental Biology, University of California, Santa Cruz, 1156 High St., Santa Cruz, CA 95064, USA
| | - Moise Danielpour
- Board of Governors Regenerative Medicine Institute, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA; Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA; Department of Neurosurgery, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA
| | - Joshua J Breunig
- Board of Governors Regenerative Medicine Institute, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA; Center for Neural Sciences in Medicine, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA; Department of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA; Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA; Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA 90095, USA.
| |
Collapse
|
4
|
Kim GB, Pacheco DRF, Saxon D, Yang A, Sabet S, Dutra-Clarke M, Levy R, Watkins A, Park H, Akhtar AA, Linesch PW, Kobritz N, Chandra SS, Grausam K, Sarmiento AA, Molina J, Sedivakova K, Gareau DS, Filbin MG, Bannykh S, Tang J, Suva M, Chen B, Danielpour M, Breunig JJ. Abstract PR11: MADR: Rapid generation of somatic mosaics with locus-specific, stably integrated transgenic elements for generation of “personalized” mouse models and human organoid tumor models. Cancer Res 2020. [DOI: 10.1158/1538-7445.camodels2020-pr11] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
In situ transgenesis methods such as virus and electroporation can create somatic transgenic mice quickly, but they lack the exquisite control over copy number, zygosity, and locus specificity. We have recently established mosaic analysis by dual recombinase-mediated cassette exchange (MADR), which permits stable labeling of mutant cells expressing transgenic elements from precisely defined chromosomal loci. MADR provides a toolkit of elements for combinatorial labeling, inducible/reversible transgene manipulation, VCre recombinase expression, and genetic manipulation of human cells. Further, we have demonstrated the versatility of MADR by creating glioma models with mixed, reporter-identified zygosity or with “personalized” driver mutations from pediatric glioma. For example, introducing H3f3a mutation variants with MADR regulates the spatiotemporal profile of glioma, and single-cell RNA and ATAC sequencing analysis demonstrates a recapitulation of developmental hierarchy seen in K27M mutant human glioma. Moreover, we have generated novel models of supratentorial ependymoma using patient-derived oncofusion transgenes. These models display a high degree of fidelity, and we now compare these models on a single-cell level with our previous models and human tumor cell transcriptomes. In addition, we now demonstrate the ability to generalize the MADR technology to other non-CNS tissues using local plasmid delivery. Finally, we have engineered human cells to allow for MADR transgenesis and somatic transgenic organoids. These combined approaches will enable researchers to discover disease mechanisms and test therapeutics in more physiologically relevant cancer models. MADR is extensible to thousands of existing mouse lines and can be adapted to human cells, providing a flexible platform to democratize the generation of somatic transgenic disease models.
This abstract is also being presented as Poster B46.
Citation Format: Gi Bum Kim, David Rincon Fernandez Pacheco, David Saxon, Amy Yang, Sara Sabet, Marina Dutra-Clarke, Rachelle Levy, Ashley Watkins, Hannah Park, Aslam Abbasi Akhtar, Paul W. Linesch, Naomi Kobritz, Swasty S. Chandra, Katie Grausam, Alberto Ayala- Sarmiento, Jessica Molina, Kristyna Sedivakova, Daniel S. Gareau, Mariella G. Filbin, Serguei Bannykh, Jie Tang, Mario Suva, Bin Chen, Moise Danielpour, Joshua J. Breunig. MADR: Rapid generation of somatic mosaics with locus-specific, stably integrated transgenic elements for generation of “personalized” mouse models and human organoid tumor models [abstract]. In: Proceedings of the AACR Special Conference on the Evolving Landscape of Cancer Modeling; 2020 Mar 2-5; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2020;80(11 Suppl):Abstract nr PR11.
Collapse
Affiliation(s)
- Gi Bum Kim
- 1Cedars-Sinai Medical Center, Los Angeles, CA,
| | | | - David Saxon
- 1Cedars-Sinai Medical Center, Los Angeles, CA,
| | - Amy Yang
- 1Cedars-Sinai Medical Center, Los Angeles, CA,
| | - Sara Sabet
- 1Cedars-Sinai Medical Center, Los Angeles, CA,
| | | | | | | | - Hannah Park
- 1Cedars-Sinai Medical Center, Los Angeles, CA,
| | | | | | | | | | | | | | | | | | | | | | | | - Jie Tang
- 1Cedars-Sinai Medical Center, Los Angeles, CA,
| | - Mario Suva
- 4Broad Institute and Massachusetts Institute of Technology, Cambridge, MA,
| | - Bin Chen
- 5University of California Santa Cruz, Santa Cruz, CA
| | | | | |
Collapse
|